A double-blind study of deflazacort and prednisone in patients with chronic inflammatory disorders.
(1991)
Journal - Arthritis and rheumatism (UNITED STATES )
Abstract :
Deflazacort and prednisone were given to 26 patients with rheumatoid arthritis, polymyalgia rheumatica, or other chronic inflammatory diseases, in a double-blind study. Deflazacort rapidly and effectively suppressed disease activity in a manner supporting its assumed therapeutic potency of 83% that of prednisone. Prednisone induced a rapid increase in the level of daily calcium excretion that was not evident with deflazacort. Cortisol secretion was acutely inhibited by prednisone, but not by deflazacort. Neither corticosteroid had a significant effect on glucose metabolism, at the doses studied. Treatment with deflazacort may be an effective alternative to prednisone treatment, with fewer adverse effects on levels of calcium and cortisol, in patients with severe inflammatory conditions warranting the use of glucocorticoids.
| ISSN : | 0004-3591 |
|---|
| Mesh Heading : | Analysis of Variance Anti-Inflammatory Agents Arthritis, Rheumatoid Bone and Bones Calcium Chronic Disease Double-Blind Method Drug Evaluation Female Glucose Humans Hydrocortisone Male Middle Aged Polymyalgia Rheumatica Prednisone Pregnenediones adverse effects metabolism drug effects metabolism metabolism metabolism blood metabolism adverse effects adverse effects |
|---|
| Mesh Heading Relevant : | therapeutic use drug therapy drug therapy therapeutic use therapeutic use |
|---|
Duration of effect of oral diphosphonate therapy in Paget's disease of bone.
(1988)
Journal - The Quarterly journal of medicine (ENGLAND )
Abstract :
The effects of the diphosphonates etidronate and clodronate were studied in 144 patients with Paget's disease. All five programmes of treatment tested induced a similar suppression of disease activity as judged by serum alkaline phosphatase concentrations, but the proportion of patients responding and the duration of responses differed significantly between programmes. The proportion responding to etidronate 5-10 mg/kg/day for six months was less than for other regimens, and the most sustained response was after treatment with clodronate 1600 mg daily for six months. More complete biochemical suppression was associated with the more prolonged responses irrespective of the regimen used.
| ISSN : | 0033-5622 |
|---|
| Mesh Heading : | Administration, Oral Alkaline Phosphatase Clodronic Acid Diphosphonates Dose-Response Relationship, Drug Drug Administration Schedule Etidronic Acid Humans Osteitis Deformans blood therapeutic use therapeutic use blood enzymology |
|---|
| Mesh Heading Relevant : | administration & dosage administration & dosage administration & dosage drug therapy |
|---|